When should we order a Next Generation sequencing test in a patient with cancer

Se ha publicado un documento de Posicionamiento titulado When should we order a Next Generation Sequencing test in a patient with cancer, en la revista E Clinical Medicine, que ha recibido ya la aprobación del editor.

Technical advances in genome sequencing and the implementation of next-generation sequencing (NGS) in clinical oncology have paved the way for individualizing cancer patient therapy based on molecular profiles. When and how to use NGS testing in the clinic is at present an unsolved issue, and new research results provide evidence favoring this approach in some types of advanced cancer. Clinical research is evolving rapidly, from basket and umbrella trials to adaptative design precision oncology clinical studies, and genomic and molecular data often displace the classical clinical validation procedures of biomarkers. In this context, physicians must be aware of the clinical evidence behind these new biomarkers and NGS tests available, in order to use them in the right moment and with a critical point of view. The status of currently available drugs that can be effective based on actionable molecular alterations, and the NGS tests currently available will be presented, offering a practical guide for the application of Clinical Precision Oncology in the real world routine practice.

Ilustración 3. Figura más relevante del documento en la que se muestra en qué ocasiones está indicada la utilización de tests de NGS.

Artículo completo aquí